Aurobindo Pharma's Telangana unit gets 3 procedural FDA observations

• Aurobindo Pharma's subsidiary Apitoria Pharma's Telangana API manufacturing unit underwent a US FDA inspection.
• The inspection, conducted from December 1-12, 2025, resulted in three procedural observations (Form 483).
• Aurobindo Pharma will respond to the FDA and stated that the observations do not impact the facility's operations.

Why It Matters: FDA observations on Aurobindo Pharma's unit signal regulatory compliance focus.